Research & Markets: India Pharma Outlook 2015: Accelerating Growth to the Next Level - Moving Up the Value Chain Beyond Gener...
March 05 2015 - 5:11AM
Business Wire
Research and Markets
(http://www.researchandmarkets.com/research/g2n4d3/india_pharma)
has announced the addition of the "India Pharma Outlook 2015:
Accelerating growth to the next level - Moving up the value chain
beyond Generics" report to their offering.
Domestic sales improved in 2014, recovering from the slump in
the 2013 caused by the market's reaction to the new drug pricing
policy. In 2015, growth is expected to continue to be healthy, as
the momentum continues and improving economic growth allow more
spending on healthcare. Sun Pharma acquisition of troubled Ranbaxy
helped it to become the leading Indian pharma company in terms of
domestic market share. Sun's in-licensing of biologics from Merck
also indicates, Indian companies willingness to advance its
pipeline towards upper value chain.
Though, US market remains the largest market for India generic
exports, it is witnessing a slowdown in product approvals and
channel consolidation which has impacted overall pricing and margin
for the industry. The increase in audits by US FDA staff on the
Indian plants of both multinationals and Indian companies have led
to an increased number of issuance of warning letters. Indian
Pharma companies are trying to diversify into other markets such as
Brazil, Mexico, Venezuela and also in some East European markets to
lower this growing dependency on the US.
The Department of Pharmaceuticals (DoP), Ministry of Chemicals
and Fertilizers, Government of India under Make in India' program
has decided to declare the year 2015 as Year of Active
Pharmaceutical Ingredients (API).' Under the Make in India'
initiative, it is expected that the government will introduce many
industry-friendly policies and incentives to give a major thrust to
the growth of Indian bulk drug industry to make it a formidable
force globally. State government of Telnagana has already announced
many incentives for the bulk manufacturing units.
Indian companies are taking center stage in Complex Generics at
US and EU markets. In Bio-similars, Indian companies will have
perhaps the largest basket aimed at Emerging Countries in 2015-20
and later for Developed countries. Though few but is the beginning
of NCE/mAb development by Indian companies is a sign of Indian
Generics moving up in the chain. Biopharma/ biotech companies in
India, S. Korea, China may have significant advantages of low-cost
manufacturing, colossal markets, and healthy government support
over potential peers from other regions. The cost barriers in the
biosimilar market lead regulated marketed giants to tie up with
Asian companies to gain access to these advantages and hedging
their bets through a joint-venture strategy.
Key Topics Covered:
- Aurobindo Pharma - Recovery so Far, So Good
- Biocon - Global Partnerships and Creating Further Value of
CRAMS -Future Drivers
- Cadila - NCE, Bio-Similars, Transdermal and Complex
Generics
- Caplin Point - Debt free Company With Strong Management - Latin
America Investment Strategy will Provide Consistent Growth
- Cipla - Fresh Leadership to Start Delivering Results Soon!
- Dishman - High Potent/Onco CRAMS to API: Will These Strategies
Work?
- Dr. Reddy's - Onco Generics and Complex Formulation Are New
Catalysts for Growth
- Glenmark - Maturing NBE/NCE pipeline Visibility to increase in
the next two years
- Jubilant Life Science - Integrated CRAMS Business - Financial
Restructuring Unlikely to Solve Key Issue
- Lupin - A True Global Indian Company - Will Enter New Phase of
Growth
- Natco - Leveraging Chemistry, Formulation and IP Strengths -
For US and India markets
- Orchid - CDR in place but Lost Confidence on Management
- Panacea Biotech : CDR Approved: Turnaround Expected From
Formulation Business
- Shilpa Medicare: A Leader in Oncology API, Expanding into
Non-Onco, Peptides and Complex Formulations - US Market the Next
Target!
- Stride Arcolab : Honeymoon Phase on- post Merger with
Shasun
- Sun Pharma, : Largest Indian generic Company venturing into
Biologic Innovation
Companies Mentioned
- Aurobindo
- Bincon
- Cadila Healthcare
- Caplin Point
- Cipla
- Dr. Reddy's
- Drishman
- Glenmark
- Jubilant Life Science
- Lupin
- Natco
- Orchid
- Panacea Biotech
- Shilpa Medicare
- Stride Arco Lab
- Sun Pharma
For more information visit
http://www.researchandmarkets.com/research/g2n4d3/india_pharma
Research and MarketsLaura Wood, Senior
Managerpress@researchandmarkets.comFor E.S.T Office Hours Call
1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT
Office Hours Call +353-1-416-8900U.S. Fax: 646-607-1907Fax (outside
U.S.): +353-1-481-1716Sector: Pharmaceuticals, Generics